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Abstract
Background: The lack of association found in several cohort studies between dietary saturated fat and coronary heart
disease (CHD) risk has renewed debate over the link between dietary fats and CHD.
Methods and Findings: We assessed the relationship between plasma phospholipid fatty acid (PFA) concentration and
incident CHD using a nested case control design within a prospective study (EPIC-Norfolk) of 25,639 individuals aged 40–79
years examined in 1993–1997 and followed up to 2009. Plasma PFA concentrations were measured by gas chromatography
in baseline samples retrieved from frozen storage. In 2,424 men and women with incident CHD compared with 4,930
controls alive and free of cardiovascular disease, mean follow-up 13 years, saturated PFA (14:0, 16:0,18:0) plasma
concentrations were significantly associated with increased CHD risk (odds ratio [OR] 1.75, 95% CI 1.27–2.41, p,0.0001), in
top compared to bottom quartiles (Q), and omega-6 polyunsaturated PFA concentrations were inversely related (OR 0.77,
0.60–0.99, p,0.05) after adjusting for age, sex, body mass index, blood pressure, smoking, alcohol intake, plasma vitamin C,
social class, education, and other PFAs. Monounsaturated PFA, omega-3 PFA, and trans PFA concentrations were not
significantly associated with CHD. Odd chain PFA (15:0, 17:0) concentrations were significantly inversely associated with
CHD (OR 0.73, 0.59–0.91, p,0.001, Q4 versus Q1). Within families of saturated PFA or polyunsaturated PFA, significantly
heterogeneous relationships with CHD were observed for individual fatty acids.
Conclusions: In this study, plasma concentrations of even chain saturated PFA were found to be positively and omega-6
polyunsaturated PFA inversely related to subsequent coronary heart disease risk. These findings are consistent with
accumulating evidence suggesting a protective role of omega-6 fats substituting for saturated fats for CHD prevention.
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Introduction
Dietary fat intake has long been implicated in the aetiology of
coronary heart disease (CHD). The adverse relationship of
transfats with CHD is widely accepted [1] such that recommen-
dations and legislation controlling use of transfats are widespread.
A meta-analysis of prospective cohort studies concluding that
there is no significant evidence that dietary saturated fat is
associated with increased risk of cardiovascular disease has
renewed debate over fat and CHD [2,3]. Randomized trials are
not always conclusive. The Women’s Health Initiative (WHI)
found no difference in cardiovascular outcomes in women
randomized to a low fat diet compared to controls [4]. However,
though the intervention group lowered total fat intake, the
polyunsaturated fat/saturated fat ratio in the WHI trial was
unchanged. It is notable that trials reporting significant differences
in cardiovascular outcomes altered dietary fatty acid (FA)
composition such as unsaturated/saturated fat ratios rather than
simply lowering total fat intakes [5–7].
Observational studies using self-reported dietary instruments
have limitations accurately assessing intake of different fats. Blood
FA profiling may provide a more objective and accurate
biomarker of FA intake [8–13]. Studies to date examining the
prospective relationship between blood FA concentrations and
CHD have had limited numbers of events, and few reported the
whole range of FAs [14–23].
We tested the hypothesis that high saturated FA and low
polyunsaturated plasma phospholipid fatty acid (PFA) status
increase CHD risk in a prospective population study and explored
the relationship of individual FAs with CHD.
Methods
The European Prospective Investigation into Cancer (EPIC)-
Norfolk is a prospective study of 25,639 men and women aged 40–
79 years in Norfolk, UK similar in characteristics to UK general
population samples, who participated in a baseline survey in
1993–1997 [24]. Participants completed a health and lifestyle
questionnaire including data on medical history, smoking, alcohol
intake, physical activity, social class, and education [25] and
attended a clinic for a health examination. Body mass index (BMI)
was calculated as weight (kilograms) divided by height (metres)
squared. Blood pressure was measured using an Accutorr non-
invasive blood pressure monitor. Blood samples were spun,
separated into 0.5 ml fractions of serum and citrated plasma,
placed in straws, sealed, and stored in liquid nitrogen. Fresh
samples were assayed for vitamin C and lipids [26].
Measurement of Plasma Phospholipid FA Concentrations
Funding was obtained for blood FA analyses in 2003–2008.
Selection of participants for analyses was based on a series of
nested case control studies with incident cases of cancers and
cardiovascular disease and up to four disease-free controls for each
case. This selection totalled about 10,000 individuals representing
two-fifths of the cohort, enriched for incident diseases. Analyses on
8,000 samples were carried out in the WHO International Agency
for Cancer Research laboratories, Lyon, France [27]. Because of
laboratory constraints in Lyon, an additional 2,000 samples were
analysed in Quotient Laboratories, UK, using the same methods
and quality control standards.
Citrated plasma straws retrieved from storage were thawed, di-
palmitoyl-D31-phosphatidylcholine Sigma) internal standard was
added to each plasma sample, total lipids extracted, and purified
by adsorption chromatography (LC-Si SPE, Supelco/Sigma).
Plasma phospholipids were analysed by gas chromatography.
Concentrations were measured by comparison of peak areas of
individual FAs with the peak area of the internal standard using
individual calibration curves. The method allowed for the analysis
of individual FAs belonging to six classes of FAs. We analysed data
for 22 FAs: saturated even chain fatty acid (SFA) (14:0, 16:0, 18:0);
odd chain FA (15:0, 17:0); omega-6 polyunsaturated, n-6
polyunsaturated fatty acid (PUFA) (18:2n-6, 18:3n-6, 20:2n-6,
20:3n-6, 20:4n-6, 22:4n-6, and 22:5n-6); omega-3 polyunsaturat-
ed, n-3 PUFA (18:3n-3, 20:5n-3, 22:5n-3, 22:6n-3); mono-
unsaturated fatty acid (MUFA) (16:1n-7, 18:1n-7cis, 18:1n-9cis,
20:1n-9); and trans-fatty acid (16:1n9trans, 18:1n9trans). The
methods are detailed in Text S1.
Ascertainment of Coronary Heart Disease Events
All participants are flagged for death certification with the
National Health Service (NHS) Central Register, UK with death
certificates coded by nosologists according to the International
Classification of Disease (ICD). CHD death was defined using
ICD9 410–414 or ICD10 I22–I25 as underlying cause of death.
Data linkage with the East Norfolk Health Authority database
identifies all hospital contacts for participants using their NHS
number. We used the ICD diagnostic codes listed to ascertain
hospital episodes for CHD. Participants were identified as
having a CHD event during follow-up if they had a hospital
admission and/or died with CHD as cause of death, with
clinical validation through medical record inspection of a sample
[28]. We ascertained fatal and non-fatal CHD events to
December 2009.
Selection of Cases and Controls
From all the individuals with available measurement of plasma
phospholipid FAs, we identified 2,424 individuals who had
incident CHD and 4,930 control individuals alive and free of
known cardiovascular disease during follow-up to 2009.
Data Analysis
FAs were grouped into six families a priori: even chain SFA, odd
chain FA, n-6 PUFA, n-3 PUFA, MUFA, and trans-fatty acid.
Analyses used SPSS Version 17.0. We compared baseline
characteristics in individuals with incident CHD and controls.
We examined the odds ratios for CHD by quartile of concentra-
tion of FA families adjusting first for age and sex, then in
multivariate models adjusting for all the other FA families, then
additionally adjusting for covariates: BMI, physical activity,
cigarette smoking habit, alcohol intake, social class, education,
plasma vitamin C (used as a biomarker of fruit and vegetable
intake [26]), personal history of diabetes, and systolic blood
pressure then finally additionally adjusting for blood cholesterol.
We repeated the analyses using FAs categorised using mol%
We then examined the odds ratios for CHD with individual
FAs. In these models we used each individual FA as a continuous
variable, adjusting for all the other individual acids as continuous
variables. To enable comparisons, the interval used to estimate the
odds ratio was approximately one standard deviation (SD) for each
FA. All models were age and sex adjusted.
Trans-fatty acids were at very low concentrations near the lower
limit of determination. Quality controlled results were only
available from the laboratory for 1,979 cases and 3,995 controls.
We analysed trans-fatty acid data two ways: coding missing data as
missing or as zero on the basis that these were extremely low
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Table 1. Baseline characteristics of men and women with incident CHD and controls EPIC-Norfolk 1993–2009.
Characteristics CHD Cases Controls p-Value
Men n= 1,595 n= 2,246
Mean (SD)
Age (y) 64.9 (7.6) 60.0 (8.0) ,0.001
BMI (kg/m2) 27.2 (3.4) 26.3 (3.1) ,0.001
Systolic blood pressure (mmHg) 143.1 (18.8) 136.1 (16.4) ,0.001
Diastolic blood pressure (mmHg) 85.7 (12.0) 83.7 (10.6) ,0.001
Total cholesterol (mmol/l) 6.25 (1.13) 6.03 (1.05) ,0.001
LDL-cholesterol (mmol/l) 4.11 (0.98) 3.92 (0.95) ,0.001
HDL-cholesterol (mmol/l) 1.17 (0.31) 1.25 (0.33) ,0.001
Triglycerides (mmol/l) 2.22 (1.23) 2.01 (1.15) ,0.001
Plasma vitamin C (mmol/l) 43.6 (18.9) 48.6 (18.2) ,0.001
Alcohol (units/week) 8.65 (11.4) 9.74 (11.1) 0.006
PFA
Total PFA (mmol/l) 4,721.9 (1215.6) 4,514.2(1196.8) 0.007
Saturated PFA (mmol/l) 1,852.8 (483.3) 1,798.0(460.5) ,0.001
Odd chain PFA (mmol/l) 27.6 (8.1) 27.2 (7.9) 0.16
Omega-6 polyunsaturated PFA (mmol/l) 1,820.5 (513.3) 1,810.0 (495.0) 0.52
Omega-3 polyunsaturated PFA (mmol/l) 362.9 (161.5) 347.7 (362.9) 0.003
Monounsaturated PFA (mmol/l) 558.2 (222.5) 531.2 (207.1) ,0.001
Trans PFA (mmol/l) 7.0 (4.1) 6.8 (4.1) 0.09
Saturated PFA (% total) 40.2 (2.7) 40.0 (2.8) 0.01
Odd chain PFA (% total) 0.6 (0.1) 0.6 (0.1) 0.05
Omega-6 polyunsaturated PFA (% total) 39.5 (3.7) 40.2(3.6) ,0.001
Omega-3 polyunsaturated PFA (% total) 7.8 (2.5) 7.6 (2.3) 0.01
Monounsaturated PFA (% total) 11.8(2.3) 11.5 (2.1) ,0.001
Trans PFA (% total) 0.1 (0.1) 0.1 (0.1) 0.66
Percent (n)
History of diabetes 7.3 (116) 2.1 (48) ,0.001
Smoking status
Never 23.7 (375) 36.1 (804) ,0.001
Former 62.9 (995) 54.8 (1221)
Current 13.3 (211) 9.1 (203)
Physical activity
Inactive 38.7 (617) 25.5 (572) ,0.001
Moderately inactive 24.5 (391) 25.8 (580)
Moderately active 20.7 (330) 24.3 (546)
Active 16.0 (265) 24.3 (547)
Education level
No qualifications 38.5 (614) 29.4 (659) ,0.001
Junior school 7.1 (113) 8.3 (187)
Senior school 44.4 (707) 44.9 (1007)
Diploma or degree 10.0(159) 17.4 (391)
Social class
Non-manual 56.5 (874) 60.4 (1339) 0.01
Manual 43.5 (672) 39.6 (878)
Women
Mean (SD) n=776 n= 2,684
Age (y) 66.5 (7.1) 59.4 (8.5) ,0.001
BMI (kg/m2) 27.3 (4.5) 25.9 (3.9) ,0.001
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values. Since findings were similar using either approach, we
present results for the more conservative approach of analysing the
data as missing.
Results
Table 1 shows baseline characteristics of the 2,434 individuals
with incident CHD (633 fatal) and 4,930 controls. Those who
developed CHD compared to controls were older, had higher
blood cholesterol, low-density lipoprotein (LDL) cholesterol,
triglycerides, and blood pressure levels and lower high-density
lipoprotein (HDL) cholesterol. They were more likely to have
diabetes, be smokers and physically inactive, and have lower
plasma vitamin C concentrations and lower mean alcohol intake.
Quantitatively, the most abundant phospholipid FAs were palmitic
(16:0), linoleic (18:2n-6), stearic (18:0), and arachidonic acid (AA)
Table 1. Cont.
Characteristics CHD Cases Controls p-Value
Systolic blood pressure (mmHg) 142.1 (19.7) 132.6 (18.0) ,0.001
Diastolic blood pressure (mmHg) 80.9 (11.1) 80.0 (10.7) ,0.001
Total cholesterol mmol/l 6.85 (1.28) 6.35 (1.20) ,0.001
LDL-cholesterol mmol/l 4.47 (1.13) 4.03 (1.06) ,0.001
HDL-cholesterol mmol/l 1.45 (0.40) 1.58 (0.42) ,0.001
Triglycerides mmol/l 2.10 (1.15) 1.64 (1.07) ,0.001
Plasma vitamin C (mmol/l) 53.1 (20.2) 59.8 (19.9) ,0.001
Alcohol (units/week) 3.1 (4.6) 4.5 (5.7) ,0.001
PFA
Total PFA (mmol/l) 5,066.0 (1333.7) 4,975.1 (1,261.8) 0.07
Saturated PFA (mmol/l) 2,048.1 (530.0) 1,980.8 (487.9) ,0.001
Odd chain PFA (mmol/l) 30.9 (9.1) 30.9 (8.5) 0.96
Omega-6 polyunsaturated PFA (mmol/l) 1,976.6 (544.0) 1,968.3 (528.6) 0.69
Omega-3 polyunsaturated PFA (mmol/l) 402.1 (173.1) 402.2 (170.7) 0.98
Monounsaturated PFA (mmol/l) 608.4 (228.8) 593.1 (203.6) 0.06
Trans PFA (mmol/l) 7.9 (4.5) 7.5(4.0) 0.02
Saturated PFA (% total) 40.5 (2.5) 39.9 (2.7) ,0.001
Odd chain PFA (% total) 0.6 (0.1) 0.6 (0.1) 0.34
Omega-6 polyunsaturated PFA (% total) 39.1 (3.5) 39.6 (3.5) ,0.001
Omega-3 polyunsaturated PFA (% total) 7.9 (2.3) 8.0 (2.4) 0.20
Monounsaturated PFA (% total) 11.8 (2.2) 11.7 (1.9) 0.40
Trans PFA (% total) 0.1 (0.1) 0.1 (0.1) 0.11
Percent (n)
History of diabetes 5.5 (46) 1.3 (36) ,0.001
Smoking status
Never 50.5 (417) 60.0 (1599) ,0.001
Former 36.6 (302) 31.2 (833)
Current 12.8 (106) 8.8 (235)
Physical activity
Inactive 45.2 (379) 25.5 (685) ,0.001
Moderately inactive 30.2 (253) 33.9 (909)
Moderately active 14.8 (124) 24.3 (652)
Active 9.8 (82) 16.3 (437)
Education level
No qualifications 63.2 (530) 47.9 (1284) ,0.001
Junior school 10.5 (88) 16.1 (433)
Senior school 22.2 (186) 25.2 (677)
Diploma or degree 4.1 (34) 10.8 (289)
Social class
Non-manual 59.1 (476) 63.8 (1676) 0.008
Manual 40.9 (330) 36.2 (949)
doi:10.1371/journal.pmed.1001255.t001
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(20:4n-6). Plasma concentrations of phospholipid trans-fatty acid
contributed less than 0.2% of the total.
Table 2 shows characteristics of the participants by quartile (Q)
of plasma phospholipid SFA. Plasma phospholipid SFA concen-
trations correlated with the other FA concentrations as well as age,
blood pressure, and lipids. A positive relationship was seen with
alcohol intake, but no consistent relationships with smoking habit,
physical activity, diabetes history, and social class.
Table 3 shows odds ratios for CHD by quartile of plasma
phospholipid FA concentration using different multivariate mod-
els. The final column shows the odds ratio for CHD using FA
concentrations as continuous variables, per approximate SD
increase. Table 4 shows similar analyses using FA mol% quartiles.
There was no overall significant relationship between total
plasma phospholipid FA concentration and CHD. The weak but
significantly positive association of CHD with plasma phospholipid
SFA concentration increased in strength and significance after
adjusting for other FA concentrations, with an odds ratio of 1.83
(95% CI 1.37–2.46, p,0.0001) in Q4 versus Q1 and a gradient of
increasing risk throughout the distribution. This association hardly
changed after multivariate adjustment apart from substantial
attenuation after adjustment for cholesterol indicating much of the
association between SFA and CHD was likely to be mediated
through blood cholesterol levels.
In contrast, plasma phospholipid odd chain FA concentrations
were inversely associated with lower CHD risk in all models. The
odds ratio for Q4 versus Q1 was 0.67 (95% CI 0.54–0.80).
Plasma phospholipid n-6 PUFA concentrations were not
significantly related to risk of CHD in the simple age- and sex-
adjusted models, but after adjusting for other FAs, the relationship
was significantly inverse. The odds ratio for CHD for Q4 versus
Q1 was 0.84 (95% CI 0.76–0.92, p,0.0001).
Plasma phospholipid n-3 PUFA concentrations inversely related
to CHD after adjusting for other FAs, but this was no longer
significant after adjusting for other covariates. Plasma phospho-
lipid MUFA concentrations showed a positive association with
CHD before and after adjusting for other FAs though this
relationship did not remain significant after adjusting for other
covariates. Plasma phospholipid trans-fatty acid concentrations
were not significantly associated with CHD.
Analyses using FA mol% rather than concentrations (Table 4)
showed similar results with plasma phospholipid SFA positively
and n-6 PUFA inversely significantly related to CHD.
Relationships were consistent in men and women in sex-
stratified analyses (unpublished data) and also after further
adjustment for dietary total energy, protein, carbohydrate, and
fibre assessed using food frequency questionnaires (Text S2).
Table 5 shows mean plasma concentrations for individual
phospholipid FAs.
Table 5 also shows odds ratios for CHD for each individual FA,
adjusting for age and sex and the other individual FAs listed, as
continuous variables and then with multivariate adjustment
excluding cholesterol. Odds ratios are shown per approximate SD
increase in plasma concentration of the relevant phospholipid FA.
Stearic acid (18:0) concentration was most strongly positively
related to CHD (OR 1.68, 1.38–2.05, p,0.0001) followed by
palmitic acid (16:0) concentration (OR 1.24, 1.07–1.45, p=0.006).
There was no observed association with myristic acid (14:0)
concentration (OR 0.98, 0.89–1.09).
Individual plasma phospholipid n-6 PUFA concentrations
showed marked heterogeneity in the relationship with CHD.
Linoleic acid (18:2n-6) was most strongly inversely related, OR
0.66 (0.58–0.75, p,0.001). Inverse associations were also observed
for AA (20:4n-6), OR 0.86 (0.76–0.97, p = 0.02), and docosapen-
tenoic acid (22:5n-6) OR 0.87 (0.78–0.96, p = 0.007). However, di-
homo-gamma-linolenic acid (DGLA) (20:3n-6) positively related to
CHD OR 1.22 (1.08–1.32, p = 0.002).
Of the n-3 PUFAs, only plasma phospholipid docosapentaenoic
acid (22:5n-3) concentration was significantly inversely associated
with CHD OR 0.72 (0.63 01500.84, p,0.00001). The main
monounsaturated FA, cis-oleic was not related to CHD (OR 1.01,
0.85–1.20). Plasma phospholipid concentration of gadoleic acid
(20:1n-9) was significantly positively related to CHD (OR
1.18,1.04–1.33, p = 0.008).
Plasma phospholipid concentrations of the two most common
trans-fatty acids measured: palmitelaidic (16:1n9 trans) and elaidic
(18:1n9 trans) were not related to CHD at these very low
concentrations.
Discussion
There was no overall association between total plasma
phospholipid FA concentration and CHD and only weak
associations were observed for each family of FAs considered in
isolation. However, when other FAs were taken into account,
plasma phospholipid SFA concentrations strongly positively and n-
6 PUFA concentrations inversely related to subsequent risk of
incident CHD. For plasma phospholipid SFA concentrations,
those in Q4 versus Q1 had approximately 75% higher CHD risk,
and for n-6 PUFA concentrations, 25% lower risk in Q4 versus
Q1. In contrast, plasma odd chain phospholipid FA concentra-
tions were inversely related to CHD with a lower risk of about
30% in Q4 versus Q1. These relationships were independent of
potential confounders including age, BMI, smoking, alcohol
intake, physical activity, plasma vitamin C, history of diabetes,
social class, education, as well as systolic blood pressure. The
relationship between plasma phospholipid SFA concentration and
CHD was attenuated after adjusting for blood cholesterol
concentrations, indicating that at least some of the relationship
could be mediated through lipid concentrations. Plasma phospho-
lipid N-3 PUFA concentrations inversely related to CHD after
adjusting for other FAs, but this relationship was no longer
apparent after multivariate adjustment. There were no overall
relationships with plasma phospholipid MUFA and trans-fatty
acid concentrations. Results were consistent using FA mol%.
Observational and intervention studies indicate that blood FA
profiles may be biomarkers for dietary FA intake though dietary
associations are stronger for the FAs such as linoleic acid and
alpha linolenic acid intake, which humans cannot produce
[8,10,13].
In this study, a deuterium-labelled phospholipid internal
standard allowed accurate determination of individual phospho-
lipid FA plasma concentrations. Previous prospective studies
examining individual FAs and CHD used percent composition
of FAs in plasma rather than plasma concentration and not all
measured the full range of FAs necessary to determine correctly
the denominator [14,15,21].
Nevertheless, several such studies reported positive relationships
between plasma phospholipid SFA composition and CHD, inverse
relationships between plasma phospholipid PUFA composition,
and no overall relationship with MUFA composition, consistent
with our findings [14,19,21]. The consistent positive associations
of SFA in cohorts using biomarker FA profiling is in marked
contrast to reports using dietary assessments of saturated fat intake
and CHD [2].
The lack of association between dietary saturated fat intake and
CHD in population studies is unsurprising given the large
measurement errors in dietary assessment of fat intake through
Plasma Fatty Acids and Coronary Heart Disease
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Table 2. Baseline characteristics of participants by quartile of plasma saturated PFA concentration.
Characteristics Quartile of Plasma-Saturated PFA Concentration
1 2 3 4 p-Value*
Men
Mean (SD)
Age (y) 61.4 (6.2) 62.1 (8.1) 62.3 (8.0) 62.6 (8.1) 0.014
BMI (kg/m2) 26.2 (3.2) 26.6 (3.2) 26.9 (3.0) 27.3 (3.4) ,0.0001
Systolic blood pressure (mmHg) 136.3 (17.1) 138.6 (17.9) 140.2 (17.8) 142.7 (17.6) ,0.0001
Total cholesterol (mmol/l) 5.54 (0.91) 6.01 (0.96) 6.43 (1.01) 6.82 (1.1) ,0.0001
LDL cholesterol (mmol/) 3.66 (0.86) 4.0 (0.92) 4.2 (0.96) 4.4 (1.01) ,0.0001
HDL cholesterol (mmol/l) 1.2 (0.30) 1.21 (0.32) 1.24 (0.35) 1.23 (0.34) 0.018
Triglyceride (mmol/l) 1.52 (0.69) 1.94 (0.85) 2.28 (1.03) 3.04 (1.71) ,0.0001
Plasma vitamin C (mmol/l) 46.6 (18.6) 45.6 (19.0) 48.3 (18.4) 45.5 (18.4) 0.004
Alcohol (units/wk) 7.4 (9.1) 8.9 (10.9) 9.9 (11.1) 12 (14.1) ,0.0001
Plasma PFA total (mmol/l) 3,412 (456) 4,253 (362) 4,991 (460) 6,384 (1,077) ,0.0001
Saturated PFA (mmol/l) 1,354 (163) 1,701 (79) 1,993 (99) 2,562 (375) ,0.0001
Odd chain PFA (mmol/l) 21.9 (4.6) 26.1 (5.1) 29.5 (6.3) 35.8 (9.3) ,0.0001
Omega-6 PFA (mmol/l) 1,399 (244) 1,709 (257) 1,974 (304) 2,466 (524) ,0.0001
Omega-3 PFA(mmol/l) 259 (97) 329 (110) 395 (138) 498 (198) ,0.0001
Monounsaturated PFA (mmol/l) 379 (86) 489 (95) 599 (146) 823 (245) ,0.0001
Trans PFA (mmol/l) 5.6 (3.4) 6.6 (3.5) 7.2 (3.9) 8.9 (5.1) ,0.0001
Percent (n)
History of diabetes 4.5 (55) 3.7 (37) 3.8 (34) 5.3 (38) 0.35
Current smoker 12.3 (149) 10.0 (99) 9.4 (84) 1.5 (82) 0.14
Physically inactive 30.7 (374) 30.7 (307) 30.7 (275) 32.3 (233) 0.70
No educational qualifications 33.3 (406) 33.1 (331) 33.3 (299) 32.9 (237) 0.79
Manual social class 42.7 (510) 40.9 (402) 50.6 (356) 39.8 (282) 0.61
Women
Mean (SD)
Age (y) 58.9 (8.9) 60.5 (8.9) 61.9 (8.6) 62.2 (8.1) ,0.0001
BMI (kg/m2) 25.7 (4.2) 25.9 (4.1) 26.3 (4.4) 26.8 (4.1) ,0.0001
Systolic blood pressure (mmHg) 130.1 (17.3) 133 (19.4) 135.7 (18) 139.6 (19.2) ,0.0001
Total cholesterol (mmol/l) 5.58 (0.90) 6.19 (1.00) 6.60 (1.13) 7.12 (1.27) ,0.0001
LDL-cholesterol (mmol/l) 3.6 (0.86) 3.97 (1.01) 4.25 (1.07) 4.5 (1.16) ,0.0001
HDL-Cholesterol (mmol/) 1.43 (0.35) 1.57 (0.41) 1.58 (0.41) 1.6 (0.45) ,0.0001
Triglycerides (mmol/l) 1.21 (0.55) 1.45 (0.68) 1.74 (0.9) 2.33 (1.48) ,0.0001
Plasma vitamin C (mmol/l) 57.6 (20.2) 58.4 (20.2) 58.8 (19.6) 58 (20.7) 0.65
Alcohol (units/wk) 3.7 (4.6) 4.1 (5.0) 4.3 (5.7) 4.4 (6.2) 0.06
Plasma total PFA (mmol/l) 3,522.2 (408.9) 4,286.5 (327.6) 4,983.1 (447.8) 6,483.5 (1035.4) ,0.0001
Saturated PFA (mmol/l) 1,390.1 (146.7) 1,707.7 (75.6) 1,998.8 (99.1) 2,599.2 (369.4) ,0.0001
Odd chain PFA (mmol/l) 23.1 (5.1) 27.4 (5.3) 31.3 (5.9) 38.2 (8.7) ,0.0001
Omega 6 PFA (mmol/l) 1,434.9 (229.6) 1,719.2 (238.3) 1,959.5 (295.7) 2,509.6 (510.2) ,0.0001
Omega 3 PFA (mmol/l) 277.5 (92.1) 340.2 (113.3) 404.5 (144.2) 526.4 (186.5) ,0.0001
Monounsaturated PFA (mmol/l) 396.5 (69.5) 492 (88.1) 589 (113.6) 810.1 (208.9) ,0.0001
Trans PFA (mmol/l) 5.6 (3.3) 6.7 (3.3) 7.5 (3.8) 9.4 (4.7) ,0.0001
Percent (n)
History of diabetes 1.4 (646) 2.2 (847) 2.8 (904) 2.6 (1,043) 0.27
Current smoker 9.8 (64) 9.4 (81) 8.1 (75) 11.4 (121) 0.1
Physically inactive 27.5 (180) 30.1 (260) 29.5 (274) 32.7 (350) 0.33
No educational qualifications 44.6 (292) 47.7 (413) 55.3 (514) 55.6 (595) ,0.0001
Manual social class 41.7(268) 38.2 (324) 33.9 (306) 36.7 (381) 0.02
*p-Value using analysis of covariance.
doi:10.1371/journal.pmed.1001255.t002
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recall errors, ubiquity of fats leading to quantification difficulties,
and critically, huge variability in FA composition of foods such
that discrimination between different fats is problematic.
Different types of fat using the conventional groupings of SFA,
n-6 and n-3 PUFA, MUFA and trans-fatty acid, have varying
biological and health effects. Though it is generally believed that
saturated and transfats are adversely and unsaturated fats
beneficially related to CHD risk [1,7], the balance between the
different fats may be more important than any single group alone.
Keys noted the saturated/unsaturated fat ratio was critical for
predicting cholesterol levels and CHD [29]. In the current study,
we found no overall relationship between total FAs and CHD.
Trials substituting unsaturated fat for saturated fat, altering the
ratios have reported more consistently reduction in cardiovascular
disease [6,7], indicating that the balance between different fats is
crucial.
Additionally even within these families, increasing evidence
indicates individual FAs have different metabolic and health
Table 3. Odds ratios for CHD in men and women, EPIC-Norfolk 1993–2009 by quartile of plasma PFA concentration, age and sex
adjusted, and multivariate adjusted and as a continuous variable, per approximate SD increase.
Plasma Phospholipid Fatty Acid Categorical Odds Ratio (95% CI) per Quartile of PFA mmol/l
Continuous Odds
Ratio (95% CI) per
SD FA Increase p-Value
1 2 3 4
Total PFAs
Age and sex adjusted 1 1.06 (0.92–1.23) 1.06 (0.92–1.23) 1.11 (0.96–1.30) 1.05 (0.99–1.11) 0.10
Age, sex, PFA, and covariates adjusteda 1 1.08 (0.92–1.26) 1.07 (0.92–1.25) 1.06 (0.90–1.25) 1.02 (0.96–1.08) 0.60
Age, sex, PFA, and covariates adjustedb 1 0.97 (0.83–1.15) 0.90 (0.76–1.07) 0.84 (0.70–1.00) 0.92 (0.87–0.99) 0.02
Saturated PFAs
Age and sex adjusted 1 1.00 (0.86–1.16) 1.06 (0.92–1.23) 1.19 (1.03–1.39) 1.09 (1.03–1.14) 0.002
Age, sex, and other PFA adjustedc 1 1.16 (0.97–1.40) 1.42 (1.12–1.79) 1.83 (1.37–2.46) 1.42 (1.23–1.61) ,0.0001
Age, sex, PFA, and covariates adjusteda 1 1.24 (1.01–1.51) 1.47 (1.14–1.90) 1.75 (1.27–2.41) 1.37 (1.19–1.50) ,0.0001
Age, sex, PFA, and covariates adjustedb 1 1.15 (0.94–1.41) 1.27 (0.98–1.64) 1.36 (0.98–1.89) 1.15 (0.99–1.33) 0.07
Odd-chain PFAs
Age and sex adjusted 1 0.88 (0.74–0.99) 0.79 (0.68–0.92) 0.84 (0.72–0.98 0.97 (0.95–1.00) 0.05
Age, sex, and other PFA adjustedc 1 0.81 (0.69–0.95) 0.69 (0.58–0.82) 0.67 (0.54–0.80) 0.94 (0.91–0.98) 0.004
Age, sex, PFA, and covariates adjusteda 1 0.83 (0.70–0.98) 0.74 (0.62–0.90) 0.73 (0.59–0.91) 0.94 (0. 90–0.97) 0.001
Age, sex, PFA, and covariates adjustedb 1 0.81 (0.68–0.95) 0.71 (0.59–0.86) 0.67 (0.54–0.84) 0.93 (0.89–0.97) ,0.001
Omega-6 polyunsaturated PFAs
Age and sex adjusted 1 0.99 (0.85–1.15) 0.97 (0.94–1.13) 1.02 (0.77–1.19) 1.01 (0.95–1.06) 0.73
Age, sex, and other PFA adjustedc 1 0.91 (0.76–1.07) 0.81 (0.66–0.99) 0.79 (0.62–0.99) 0.84 (0.76–0.92) ,0.0001
Age, sex, PFA, and covariates adjusteda 1 0.93 (0.77–1.11) 0.82 (0.66–1.01) 0.77 (0.60–0.99) 0.83 (0.75–0.92) 0.001
Age, sex, PFA, and covariates adjustedb 1 0.89 (0.74–1.07) 0.79 (0.64–0.98) 0.75 (0.59–0.97) 0.85 (0.77–0.95) 0.003
Omega-3 polyunsaturated PFAs
Age and sex adjusted 1 1.03 (0.89–1.20) 1.00 (0.96–1.16) 0.94 (0.81–1.09) 0.96 (0.90–1.02) 0.19
Age, sex, and other PFA adjustedc 1 1.02 (0.87–1.19) 0.93 (0.78–1.10) 0.85 (0.70–1.02) 0.89 (0.82–0.97) 0.006
Age, sex, PFA, and covariates adjusteda 1 1.08 (0.92–1.28) 1.09 (0.90–1.31) 1.10 (0.90–1.36) 1.01 (0.92–1.11) 0.82
Age, sex, PFA, and covariates adjustedb 1 1.05 (0.89–1.25) 1.04 (0.87–1.26) 1.07 (0.87–1.32) 1.02 (0.93–1.12) 0.65
Monounsaturated PFAs
Age and sex adjusted 1 1.05 (0.92–1.22) 1.12 (0.97–1.30) 1.15 (0.99–1.34) 1.08 (1.03–1.13) 0.003
Age, sex, and other PFA adjustedc 1 1.10 (0.93–1.30) 1.17 (0.96–1.43) 1.17 (0.92–1.48) 1.10 (1.01–1.20) 0.04
Age, sex, PFA, and covariates adjusteda 1 0.96 (0.80–1.16) 0.96 (0.78–1.19) 0.89 (0.69–1.16) 0.99 (0.90–1.09) 0.86
Age, sex, PFA, and covariates adjustedb 1 0.97 (0.81–1.17) 1.01 (0.81–1.25) 0.97 (0.74–1.37) 1.04 (0.95–1.15) 0.39
Trans PFAs
Age and sex adjusted 1 0.91 (0.77–1.08) 0.95 (0.81–1.13) 1.01 (0.86–1.20) 1.01 (0.96–1.07) 0.82
Age, sex, and other PFA adjustedc 1 0.95 (0.79–1.11) 0.97 (0.81–1.15) 1.00 (0.84–1.20) 1.00 (0.94–1.07) 0.94
Age, sex, PFA, and covariates adjusteda 1 0.90 (0.75–1.08) 0.92 (0.76–1.11) 0.93 (0.76–1.13) 0.99 (0.92–1.05) 0.66
Age, sex, PFA, and covariates adjustedb 1 0.88 (0.73–1.06) 0.90 (0.74–1.09) 0.89 (0.73–1.09) 0.98 (0.91–1.05) 0.50
p-Values derived from Wald statistic.
aBMI, smoking, alcohol intake, physical activity, plasma vitamin C, social class, education, diabetes, systolic blood pressure.
bBMI, smoking, alcohol intake, physical activity, plasma vitamin C, social class, education, diabetes, systolic blood pressure, and cholesterol.
cPFAs grouped in categories.
doi:10.1371/journal.pmed.1001255.t003
Plasma Fatty Acids and Coronary Heart Disease
PLoS Medicine | www.plosmedicine.org 7 July 2012 | Volume 9 | Issue 7 | e1001255
effects. Such heterogeneity in the relationship between individual
SFAs or n-6 PUFAs and CHD noted in several prospective studies
may explain variable associations of total SFAs and n-6 PUFA
with CHD in different populations depending on the distribution
of individual FAs.
In this study, stearic acid (18:0) plasma phospholipid concen-
tration was the SFA most strongly positively related to CHD,
followed by palmitic acid (16:0) concentration. Myristic acid (14:0)
was not related to CHD risk. Of the n-3 PUFAs, only
docosapentaenoic acid, (22:5n-3) plasma phospholipid concentra-
tion inversely related to CHD. This is not surprising as n-3PUFAs
have primarily been associated with arrhythmic cardiac death
[30].
Of the n-6PUFAs, the plasma phospholipid concentration of
linoleic acid (18:2n-6) and AA (20:4n-6) inversely related to CHD,
but DGLA (20:3n-6) positively related to CHD.
The n-6 PUFA AA (22:4n6) is the substrate for series 2
thromboxanes and prostanoids metabolites believed to be proin-
flammatory and thrombotic, in contrast to DGLA (22:3n6) for
which the eicosanoid metabolites, series 1 thromboxanes and
prostanoids are thought to be anti-inflammatory and antithrom-
botic [31]. DGLA is therefore believed to be beneficial for CHD in
contrast to AA. However, we observed the converse, a positive
relationship between DGLA and negative relationship between
AA and CHD, unexpected findings also noted by other
prospective studies [14,18,19,21], including the ARIC study (282
CHD events) [21], a nested case control study within the Multiple
Risk Factor Intervention Trial (94 CHD cases, 94 controls) [19], a
Swedish cohort (153 CHD events) [18], and the Whitehall study
(116 events) [14]. The Swedish investigators hypothesised their
observed inverse relationship between AA/DGLA ratio and CHD
reflected activity of delta5-desaturase enzyme [18].
Results for odd chain FAs (15:0; 17:0) require comment.
Though often included with SFAs, they are metabolised differently
from even chain SFAs. The 15:0 and 17:0 FAs are ruminant
specific and suggested to be biomarkers of milk or dairy intake
[12]. Studies reporting on odd chain FAs have inconsistent results.
The Nurses Health Study (166 cases, 327 controls) reported an
odds ratio of 2.36 for CHD between top and bottom tertiles of odd
chain plasma FA composition [20]. In contrast, a Swedish cohort
(446 cases, 558 controls) reported a standardized OR for CHD of
0.76 in women and 0.91 in men [23]. We found an odds ratio of
0.67 in Q4 versus Q1 for odd chain FAs. Despite the contribution
of dairy produce to saturated FA composition of the diet, a recent
Table 4. Odds ratios for CHD in men and women, EPIC-Norfolk 1993–2009 by quartile of plasma PFA mol%, age and sex adjusted,
and multivariate adjusted and as a continuous variable, per approximate standard deviation increase.
Plasma Phospholipid Fatty Acid
Categorical Odds Ratio (95% CI) per Quartile of Mol%
PFA
Continuous Odds Ratio
(95% CI) per SD % FA
Increase p-Value
1 2 3 4
Saturated even chain PFAs
Age and sex adjusted 1 1.10 (0.95–1.28) 1.22 (1.05–1.42) 1.34 (1.16–1.56) 1.18 (1.10–1.28) ,0.0001
Age, sex, and covariates adjusteda 1 1.13 (0.96–1.32) 1.21 (1.04–1.42) 1.25 (1.7–1.46.) 1.14 (1.05–1.24) 0.002
Age, sex, covariates, and cholesterol adjustedb 1 1.11 (0.94–1.30) 1.19 (1.01–1.39) 1.21 (1.03–1.42) 1.11 (1.02–1.21) 0.01
Odd-chain PFAs
Age and sex adjusted 1 0.85 (0.73–0.98) 0.74 (0.64–0.87) 0.77 (0.66–0.89) 0.89 (0.84–0.94) ,0.0001
Age, sex, and covariates adjusteda 1 0.90 (0.76–1.05) 0.84 (0.72–0.99) 0.87 (0.74–1.03) 0.93 (0.88–0.99) 0.02
Age, sex, covariates, and cholesterol adjustedb 1 0.91 (0.77–1.07) 0.87 (0.74–1.03) 0.93 (0.79–1.10) 0.93 (0.88–0.99) 0.02
Omega-6 Polyunsaturated PFAs
Age and sex adjusted 1 0.92 (0.79–1.06) 0.82 (0.71–0.96) 0.82 (0.71–0.95) 0.90 (0.85–0.95) ,0.0001
Age, sex, and covariates adjusteda 1 0.92 (0.79–1.08) 0.84 (0.72–0.98) 0.95 (0.72–0.99) 0.90 (0.85–0.96) 0.001
Age, sex, covariates, and cholesterol adjustedb 1 0.92 (0.79–1.08) 0.85 (0.73–1.00) 0.86 (0.73–1.00) 0.92 (0.87–0.98) 0.01
Omega-3 polyunsaturated PFAs
Age and sex adjusted 1 1.02 (0.88–1.18) 0.83 (0.72–0.97) 0.84 (0.73–0.98) 0.92 (0.86–0.98) 0.01
Age, sex, and covariates adjusteda 1 1.07 (0.92–1.25) 0.89 (0.76–1.05) 1.00 (0.85–1.17) 1.00 (0.93–1.08) 0.97
Age, sex, covariates, and cholesterol adjustedb 1 1.10 (0.94–1.30) 0.90 (0.77–1.05) 0.97 (0.84–1.26) 1.00 (0.93–1.07) 0.98
Monounsaturated PFAs
Age and sex adjusted 1 0.91 (0.78–1.05) 0.99 (0.85–1.14) 1.20 (1.04–1.39) 1.10 (1.04–1.15) ,0.001
Age, sex, and covariates adjusteda 1 0.90 (0.77–1.05) 0.92 (0.79–1.08) 1.03 (0.88–1.20) 1.04 (0.99–1.11) 0.16
Age, sex, covariates, and cholesterol adjustedb 1 0.93 (0.80–1.09) 0.95 (0.81–1.11) 1.06 (0.90–1.24) 1.03 (0.98–1.09) 0.24
Trans PFAs
Age and sex adjusted 1 0.91 (0.77–1.08) 0.95 (0.81–1.12) 1.01 (0.86–1.20) 1.01 (0.96–1.07) 0.82
Age, sex, and covariates adjusteda 1 0.84 (0.70–1.00) 0.90 (0.75–1.07) 0.95 (0.79–1.13) 1.00 (0.94–1.06) 0.99
Age, sex, covariates, and cholesterol adjustedb 1 0.84 (0.71–1.01) 0.90 (0.75–1.08) 0.96 (0.80–1.15) 1.00 (0.94–1.06) 0.98
p-Value derived from Wald statistic. PFAs grouped according to quartiles of mo% total FAs.
aBMI, smoking, alcohol intake, physical activity, plasma vitamin C, social class, education, diabetes, systolic blood pressure.
bBMI, smoking, alcohol intake, physical activity, plasma vitamin C, social class, education, diabetes, systolic blood pressure, and cholesterol.
doi:10.1371/journal.pmed.1001255.t004
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reappraisal concluded there is no consistent evidence that dairy
food consumption is associated with a higher risk of cardiovascular
disease [32]. Milk or dairy consumption has been reported to be
associated with lower risk of metabolic syndrome [33], heart
disease [34], and hypertension [35], and the DASH trial reported
lower blood pressure with a dietary intervention including low fat
milk [36]. These associations need further exploration and
confirmation.
The study has limitations. Although we conducted a large
number of statistical tests, the analyses for the main FA families were
designed using a priori hypotheses. Despite not being in line with the
putative biological effects of their metabolites, the AA and DGLA
results are consistent with previous studies in different settings in the
US and Europe. The results for odd chain FAs have some previous
support, but will need confirmation in future studies.
We only measured the two most common trans-fatty acids
(16:1n9trans, 18:1n9trans). Though we were unable to assess the
18:2 transisomers associated with CHD in other studies [37], at
the very low concentrations in a range more typical of European
populations [11], there was little power to assess the trans-fatty
acid–CHD relationship. We controlled for the major lifestyle and
demographic factors related to CHD risk but cannot exclude
residual confounding with other unknown factors.
We used only plasma FAs measured one point in time to
characterise individuals. There is likely to be large intraindividual
variation in FAs but such random measurement error is likely to
attenuate any relationships, rather than produce spurious associ-
ations.
Future studies examining the relationship between FAs and
CHD need to consider heterogeneity in the biological and health
effects of individual FAs as well as the overall FA profile and
balance between FAs. The ability to assess these associations in
human populations has been constrained by the limitations of
assessing dietary fat intake. Biochemical measures offer more
Table 5. Mean plasma concentrations of individual PFAs in men and women, EPIC-Norfolk and age- and sex-adjusted odds ratios
for CHD.
PFA
Plasma
Concentration
mmol/l (SD) mol%
Odds Ratios CHD (95%
CI) Age, Sex, and PFA
Adjusteda p-Value
Odds Ratios CHD
(95% CI) Multivariate
Adjustedb p-Value
Total PFAs 4,768.4(1266) 100 1.05 (0.99–1.11) 0.10 1.02 (0.96–1.08) 0.60
Saturated even chain PFA 1,905.0 (492.4) 39.9 1.42 (1.23–1.61) ,0.0001 1.37 (1.19–1.58) ,0.0001
14:0 myristic 17.6 (10.6) 0.98 (0.89–1.09) 0.71 0.97 (0.87–1.08) 0.97
16:0 palmitic 1,256.8 (332.3) 1.24 (1.07–1.45) 0.006 1.37 (1.16–1.62) ,0.001
18:0 stearic 628.0 (184.0) 1.68 (1.38–2.05) ,0.0001 1.56 (1.25–1.93) ,0.0001
Odd chain fatty PFA 29.1(8.5) 0.6% 0.94 (0.91–0.98) 0.004 0.94 (0.90–0.97) 0.001
15:0 pentadecanoic 9.2(3.1) 0.95 (0.86–1.04) 0.28 0.98 (0.89–1.09) 0.79
17:0 heptadecanoic/margaric 18.4 (5.9) 0.91 (0.83–1.01) 0.07 0.91 (0.82–1.01) 0.07
Omega-6 polyunsaturated PFA 1,888.9(492.4) 39.6% 0.84 (0.76–0.92) ,0.0001 0.83 (0.75–0.92) 0.001
18:2n-6 linoleic 1,166.5(330.0) 0.66 (0.58–0.75) ,0.0001 0.70 (0.61–0.81) ,0.0001
18:3n-6 gamma-linolenic 6.0 (5.2) 1.05 (0.98–1.13) 0.18 1.05 (0.97–1.14) 0.21
20:2n-6 eicosadienoic 20.5(8.8) 1.06 (0.95–1.18) 0.33 1.09 (0.97–1.23) 0.14
20:3n-6 dihomo-gamma-linolenic 194.6(83.6) 1.22 (1.08–1.39) 0.002 1.06 (0.92–1.22) 0.44
20:4n-6 arachidonic 475.2(163.9) 0.86 (0.76–0.97) 0.018 0.84 (0.74–0.97) 0.013
22:4n-6 docosatetrahexanoic 16.6 (9.9) 1.10 (1.00–1.20) 0.04 1.08 (0.98–1.18) 0.11
22:5n-6 docosapentenoic 9.7(5.8) 0.87 (0.78–0.96) 0.007 0.87 (0.77–0.97) 0.016
Omega-3 polyunsaturated PFA 377.0(165.7) 7.9% 0.89 (0.82–0.97) 0.006 1.01 (0.92–1.11) 0.82
18:3n-3 alpha-linolenic 11.4(6.4) 0.97 (0.88–1.07) 0.58 0.98 (0.89–1.09) 0.70
20:5n-3 eicosapentanoic 63.1(45.2) 1.01 (0.92–1.12) 0.83 1.00 (0.89–1.11) 0.95
22:5n-3 docosapentaenoic 65.1(28.0) 0.72 (0.63–0.84) ,0.0001 0.84 (0.72–0.98) 0.03
22:6n-3 docosahexanoic 237.4 (106.2) 0.95 (0.84–1.07) 0.39 0.96 (0.85–1.09) 0.56
Monounsaturated PFA 568.4 (213.5) 11.9% 1.10 (1.01–1.20) 0.04 0.99 (0.90–1.09) 0.86
16:1n-7 palmitoleic 38.4 (19.5) 0.98 (0.84–1.14) 0.76 0.91 (0.77–1.07) 0.26
18:1n-7 cis cis-vaccenic 45.9 (17.5) 1.10 (1.00–1.22) 0.06 1.17 (1.06–1.31) 0.003
18:1n-9 cis cis-oleic 474.0 (184.9) 1.01 (0.85–1.20) 0.90 0.91 (0.75–1.09) 0.31
20:1n-9 gadoleic 7.6 (6.1) 1.18 (1.04–1.33) 0.008 1.20(1.05–1.36) 0.006
Trans PFA 7.2 (4.1) 0.2% 1.00 (0.94–1.07) 0.94 0.99 (0.92–1.05) 0.66
16:1n9 trans palmitelaidic 2.4 (1.5) 0.97 (0.90–1.05) 0.48 0.93 (0.85–1.01) 0.08
18:1n9 trans elaidic 4.8 (3.5) 1.01 (0.93–1.09) 0.88 0.99 (0.91–1.07) 0.74
aAdjusted for age, sex, and all individual PFAs in the same model for individual PFAs, families of PFA for the families, all as continuous variables.
bAdjusted for age, sex, other PFA, BMI, smoking, physical activity, alcohol intake, social class, education, blood pressure.
doi:10.1371/journal.pmed.1001255.t005
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objective and specific biomarkers, which may provide greater
insight into exogenous dietary factors as well as endogenous
metabolic processes which influence risk of chronic diseases.
These results indicate that high plasma phospholipid SFA and
low PUFA (predominantly n-6 FAs) are associated with increased
CHD risk but neither can be considered in isolation. It is beyond
the remit of the current study to quantify in absolute amounts the
relationship between blood FA concentrations and dietary intake
of foods and nutrients, It is not clear how far the associations
reflect complex interactions between dietary fat intake per se and
FA metabolism, which may have both genetic and other
exogenous influences. Nevertheless, the major sources of dietary
n-6 PUFA, i.e., linoleic acid in most western populations, are
vegetable oils such as sunflower oil, corn oil, soybean oil, and
canola oil, and nuts and seeds.
While dietary recommendations should focus on general
patterns of food intake rather than individual nutrients [38],
recommendations still need to be based on knowledge of the
biological roles of different nutrients and balance between different
nutrients in foods. Just as recommendations now acknowledge
differences in health effects of different families of fats, so they
should evolve to reflect increasingly discriminating understanding
of individual FA metabolism, and their interactions. Early
guidelines to prevent CHD recommended reductions in saturated
fat but little consistency as to what might be substituted: other fats,
protein, or carbohydrate. Our results add to the accumulating
evidence that substitution of saturated fat by n-6 polyunsaturated
fat may have more CHD benefits [33,39,40].
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Editors’ Summary
Background. Coronary heart disease (CHD) is a condition
caused by a build-up of fatty deposits on the inner walls of
the blood vessels that supply the heart, causing the affected
person to experience pain, usually on exertion (angina). A
complete occlusion of the vessel by deposits causes a heart
attack (myocardial infarction). Lifestyle factors, such as diet
(particularly one high in fat), contribute to causing CHD.
There are different types of fat, some of which are thought to
increase risk of CHD, such as saturated fat, typically found in
meat and dairy foods. However, others, such as unsaturated
fats (polyunsaturated and monounsaturated fats) found in
foods such as vegetable oils, fish, and nuts, may actually help
prevent this condition.
Why Was This Study Done? Although there have been
many studies investigating the role of different types of
dietary fat in coronary heart disease, it is still not clear
whether coronary heart disease can be prevented by
changing the type of dietary fat consumed from saturated
to unsaturated fats or by lowering all types of dietary fat.
Furthermore, many of these studies have relied on partici-
pants recalling their dietary intake in questionnaires, which is
an unreliable method for different fats. So in this study, the
researchers used an established UK cohort to measure the
levels of different types of fatty acids in blood to investigate
whether a diet high in saturated fatty acids and low in
unsaturated fatty acids increases CHD risk.
What Did the Researchers Do and Find? The researchers
used a selection of 10,000 participants (all men and women
aged 40–79 years) from the prospective European Prospec-
tive Investigation into Cancer (EPIC)-Norfolk cohort. Blood
samples from the selected participants taken at the start of
the study in 1993–1997 were analyzed to determine levels of
specific fatty acids. Participants were followed up till 2011.
The researchers identified 2,424 participants who were
subsequently diagnosed with CHD using death certificates
and hospital discharge data and matched these with 4,930
controls who were still alive and free of known coronary
disease. The researchers grouped the type of blood fatty
acids identified in the blood samples into six families (even
chain saturated fatty acid, odd chain saturated fatty acid,
omega-6 polyunsaturated fatty acid, omega-3 polyunsatu-
rated fatty acid, monounsaturated fatty acid, and trans-fatty
acid), which represented saturated and unsaturated fatty
acids. Using statistical methods, the researchers then
compared the risks of developing CHD between cases and
controls by the concentration of fatty acid families after
adjusting for age and sex and other factors, such as body
mass index, physical activity, and smoking. Using these
methods, the researchers found that there was no overall
significant relationship between total blood fatty acid
concentration and CHD but there was a positive association
with increasing blood saturated fatty acid concentration
after adjusting for other fatty acid concentrations, with an
odds ratio of 1.83 comparing higher versus lower concen-
trations. This risk was attenuated after adjusting for
cholesterol levels, indicating that much of the association
between saturated fatty acid and CHD is likely to be
mediated through blood cholesterol levels. In contrast,
blood omega-6 poly-unsaturated fatty acid concentrations
were associated with lower CHD risk. Blood monounsaturat-
ed fatty acids, omega-3 poly-unsaturated fatty acids, and
trans-fatty acids were not consistently associated with CHD
risk. The authors also noted that within families of fatty acids,
individual fatty acids related differently to CHD risk.
What Do These Findings Mean? These findings suggest
that plasma concentrations of saturated fatty acids are
associated with increased risk of CHD and that concentra-
tions of omega-6 poly-unsaturated fatty acids are associated
with decreased risk of CHD. These findings are consistent
with other studies and with current dietary advice for
preventing CHD, which encourages substituting foods high
in saturated fat with n-6 polyunsaturated fats. The results
also suggest that different fatty acids may relate differently
to CHD risk and that the overall balance between different
fatty acids is important. However, there are limitations to this
study, such as that factors other than diet (genetic
differences in metabolism, for example) may cause changes
to blood fatty acid levels so a major question is to identify
what factors influence blood fatty acid concentrations.
Nevertheless, these findings suggest that individual fatty
acids play a role in increasing or decreasing risks of CHD.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001255.
N Information about the EPIC-Norfolk study is available
N The American Heart Foundation provides patient-friendly
information about different dietary fats as does Medline
N The British Heart Foundation also provides patient-friendly
information on heart conditions
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